TNFRSF1B and ovarian carcinoma: Furthermore, TNFR2 expressing Tregs accumulation has been observed and related to adverse clinical outcome in lung cancer (35, 36), ovarian cancer (37, 38), acute myelocytic leukemia (38–40) and cervical cancer (41).